---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-275811"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-06-18T20:05:38+00:00"
generated_at: "2026-06-18T20:12:38.362903+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Mirum Pharma annual meeting: all director nominees elected, auditor ratified, say-on-pay approved

## Summary
- Stockholders elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors with 39.6M, 40.3M, and 32.3M votes for, respectively.
- Ratification of Ernst & Young as independent auditor for FY 2026 passed with 49.99M votes for, 5,674 against.
- Advisory vote on executive compensation approved with 44.5M votes for, 1.87M against, and 3.6M broker non-votes.
- As of record date April 20, 2026, 60,977,841 shares were outstanding and entitled to vote.

## SEC filing metadata
- accession: 0001193125-26-275811
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-06-18T20:05:38+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312526275811/0001193125-26-275811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312526275811/d74563d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-275811
- JSON: https://secwatch.observer/filing/0001193125-26-275811.json
- Plain text: https://secwatch.observer/filing/0001193125-26-275811.txt

## Key facts
- Shareholder Votes
  Mirum Pharmaceuticals, Inc. shareholders approved Election of three Class I directors at the 2026-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-15
  source text: The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312526275811/0001193125-26-275811-index.htm
- Shareholder Votes
  Mirum Pharmaceuticals, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-15
  source text: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312526275811/0001193125-26-275811-index.htm
- Shareholder Votes
  Mirum Pharmaceuticals, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-15
  source text: The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312526275811/0001193125-26-275811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.